Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History

Nuvo Research Inc T.NRI

Sector: Healthcare | Sub-Sector: Drug Manufacturers - Specialty & Generic
Alternate Symbol(s):  NRIFF | NRIFD

Nuvo Research, Inc. is a Canadian specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units: the Topical Products and Technology (TPT) Group (formerly the Pain Group) and the Immunology Group.
Price: $7.57 | Change: $-0.23 | %Change: -2.95%
Volume: 82,016 | Day High/Low: 8.00/7.35 | 52 Week High/Low: 8.33/1.66
View modes: 
5 stars

RE:NRI IS A TAKEOVER TARGET AT THIS LEVEL

Never going to happen at anything this low. Management won't sell and neither will the funds. The short-term speculators are exiting as expected. This could be a rarity for Nuvo - the stock is at...read more
5 stars

NRI IS A TAKEOVER TARGET AT THIS LEVEL

Any decent pharma could come in today and offer $7 share.  With the shareholders as unhappy with managment as they have been, and rightly in many ways, they would probably agree to sell.  Think about...read more
5 stars

Same deal as with Mallincroft

Except they get the $45 million up front . 20% royalty and the same 8 year manufacturing deal that should see annual revenues of about $12 million on $75 million in annual sales. Over the life if this...read more
4 stars

RE:Gap between $4.87 and $4.96

Pretty well looks like it did fill the gap. Certainly came close so far.  rate and reply
3 stars

Gap between $4.87 and $4.96

This stock is legend for needing to fill gaps.  I personally would not touch it, until it filled that gap down to $4.87.  Buyers beware  rate and reply
3 stars

RE:RE:Price sinking fast...another great vote of confidence in NRI

I doubt anyone really knows the true reason why it stays so undervalued, but my best guess is that the company still is not profitable. Selling US Pensaid rights gives us a bit a cash but it doesnt...read more
4 stars

RE:RE:Price sinking fast...another great vote of confidence in NRI

1wascallywabbit wrote: is there anyone here on this BB that is a seller this morning? Can you please explain why? I must be missing something if we have over $6 cash and u think you are lucky to sell...read more
5 stars

RE:RE:Price sinking fast...another great vote of confidence in NRI

It's simple - it's about the shareholder, not the company. People NEED their money, and they wait for the next piece of good news and sell into the excitement. Also, the oil sector is artificially...read more
2 stars

RE:Price sinking fast...another great vote of confidence in NRI

is there anyone here on this BB that is a seller this morning? Can you please explain why? I must be missing something if we have over $6 cash and u think you are lucky to sell for $5.  rate and reply
3 stars

Price sinking fast...another great vote of confidence in NRI

get these nutcases out of leadership!  rate and reply
0 stars

RE:RE:No running royalty payments?

Thanks 2j3kl.  Did they mention the royalty rate or payment amount for the supply agreement?  Is it 5%? Thanks again.  rate and reply
0 stars

RE:No running royalty payments?

the 8 year supply agreement means Nuvo will manufacture p2 for horizon for 8 years.  rate and reply
5 stars

RE:RE:Pennsaid U.S rights sold for US$45 million (=C$50 million)..

2j3kl- I am beginning to believe that #8 (monetization of all assets) is a distinct possibility in early 2015. The balance sheet is now very clean, and there are no very significant marketing...read more
3 stars

No running royalty payments?

Sorry, I'm unable to listen to the cc right now.  The 2 news releases (Nuvo's and Horizon's) both seem to refer to a 'one time payment' (Horizon's is a more explicit - and as an aside, I really wish...read more
3.5 stars

RE:Pennsaid U.S rights sold for US$45 million (=C$50 million)..

It was a very interesting CC. Some points that I felt were significant. 1.EU will be a more competitive market for Pennsaid products, but being FDA approved, P2 should be on a very competitive basis...read more
5 stars

RE:Bid/Ask

$5.10 - well below cash value. That tells you how much faith there is in Management handling this cash well. I feel that perception will change, but you just never know. I am hanging in til at least...read more
3 stars

Bid/Ask

Now $5.30 but I think we will see over $6 very soon - maybe today, and if the Market has any faith at all in Management, this will be over $10 very soon.  rate and reply
2.5 stars

NRI CASH PER SHARE $6 TRADING UNDER CASH

When a company is trading at under its cash value, it has a portfolio of products and a promising multi-billion allergy drug in phase 2.  Next move Nasdaq.  In the US in the right hands this is a $15...read more
5 stars

Pennsaid U.S rights sold for US$45 million (=C$50 million)..

uvo Research® Sells PENNSAID® 2% U.S. Rights for US$45 Million to Horizon Pharma 07:00 EDT Friday, October 17, 2014 -- Nuvo to Host Conference Call/Webcast at 8:30 a.m. ET -- MISSISSAUGA, ON,...read more
2.5 stars

RE:My apology...I was a bit conservative on P2 sale

So, they got $5 million US more than my $40 m value. Interestingly, Pennsaid was not sold and NR holds the rights to both outside the US and is actively seeking a new partner for those areas. So, we...read more

Private Equity


Own a piece of our private equity marketplace: Limited to 50 members.

Click here to watch video 4

How to invest in private equity without writing a $1 million check.

Click here to watch video 3

Why the wealthy are 23x wealthier than the average investor.

Click here to watch video 2

Private Equity: Find out why it returned 16% p.a. for 10 years.


Click here to watch video 1